KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Gross Profit (2019 - 2025)

Historic Gross Profit for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to $46.0 million.

  • Esperion Therapeutics' Gross Profit rose 3398.94% to $46.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.8 million, marking a year-over-year decrease of 2664.74%. This contributed to the annual value of $263.7 million for FY2024, which is 26091.94% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Gross Profit of $46.0 million as of Q3 2025, which was up 3398.94% from $53.8 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Gross Profit ranged from a high of $127.7 million in Q1 2024 and a low of $6.2 million during Q1 2021
  • Moreover, its 5-year median value for Gross Profit was $20.6 million (2023), whereas its average is $30.7 million.
  • Its Gross Profit has fluctuated over the past 5 years, first crashed by 8165.63% in 2021, then soared by 90702.06% in 2024.
  • Over the past 5 years, Esperion Therapeutics' Gross Profit (Quarter) stood at $10.3 million in 2021, then surged by 41.95% to $14.7 million in 2022, then skyrocketed by 41.89% to $20.8 million in 2023, then skyrocketed by 109.07% to $43.5 million in 2024, then rose by 5.84% to $46.0 million in 2025.
  • Its Gross Profit was $46.0 million in Q3 2025, compared to $53.8 million in Q2 2025 and $33.5 million in Q1 2025.